pharma webinar

What’s Next for U.S. Drug Pricing and Domestic Production

August 7, 2020

APCO hosted a discussion around the recent Trump Administration executive orders on drug pricing and the announcement of using the Defense Production Act to spur increased U.S.-based pharmaceutical ingredients manufacturing as the nation gears up to come back stronger. Panelists were APCO IAC member and policy expert Dr. Kavita Patel; PhRMA General Counsel and former HHS acting general counsel, Jim Stansel; former FDA Chief Counsel and Sidley partner Becky Wood. I had the privilege of serving as moderator.

The discussion covered a range of timely topics including the policy and political ramifications of the executive orders, how drug pricing actions will resonate considering the pandemic and which of these policies might move forward in 2021. We fully discussed the pharmaceutical industry’s strong reaction in opposing the most favored nation pricing proposal, its support of the effort to reform the system of providing rebates to “middlemen” and the challenges of drug importation. The discussion about the Kodak decision focused on the overall supply chain the challenges and opportunities.

Watch the full event here:

Related Articles

United Nations Headquarters with waving flags in New York, USA

Perspectives

Youth at the Heart of Global Health 

August 28, 2025
Azerbaijan and Armenian flags

Perspectives

The Armenia-Azerbaijan Deal: Securing Stability in the Caucasus and a New Eurasian Trade Network 

August 21, 2025
EU and China leaders

On Site, Perspectives

Partners, Competitors or Rivals? The EU-China Summit and the Future of the Bilateral Relationship 

August 12, 2025